Literature DB >> 25558558

Prognostic value of neutrophil/lymphocyte ratio in patients with pulmonary embolism.

Umut Yücel Cavuş1, Sinan Yildirim, Ertan Sönmez, Cağatay Ertan, Ozcan Ozeke.   

Abstract

AIM: Preliminary evidence suggests that inflammation plays a role in the development and prognosis of pulmonary embolism (PE). We used the neutrophil/lymphocyte ratio (NLR) as a measure of systemic inflammation and investigated its association with PE.
MATERIALS AND METHODS: A total of 266 patients who were diagnosed with PE and a control group of 124 age- and sex-matched healthy subjects were included in this study. We further classified the PE patients into 2 groups: those who survived and those who died in the first 30 days. Baseline NLR was measured by dividing neutrophil count to lymphocyte count and was compared between the groups.
RESULTS: Median NLR was significantly higher among patients with PE compared to the healthy control group (3.9 (interquartile range (IQR): 5.0) vs. 1.9 (IQR: 0.6), P < 0.001). Of the 266 patients with PE, 16 (6%) died within 1 month. Median NLR was significantly higher among PE patients who died compared to those who survived, as well (3.7 (IQR: 4.3) vs. 9.0 (IQR: 7.9), P < 0.001). The optimal cut-off values, sensitivities, and specificities of NLR for predicting PE and in-hospital mortality of PE were >2.565 and >5.465, 70.3% and 75.0%, and 92.7% and 67.6%, respectively. Multiple logistic regression analysis showed that NLR values of >5.465 could define those patients with a mortal clinical course independently (odds ratio: 13.446, 95% confidence interval: 3.141-57.566, P < 0.001).

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25558558

Source DB:  PubMed          Journal:  Turk J Med Sci        ISSN: 1300-0144            Impact factor:   0.973


  7 in total

1.  Assessment of Prognostic Value of Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in Patients with Pulmonary Embolism.

Authors:  Mehmet Baran Karataş; Göktürk İpek; Tolga Onuk; Barış Güngör; Gündüz Durmuş; Yiğit Çanga; Yasin Çakıllı; Osman Bolca
Journal:  Acta Cardiol Sin       Date:  2016-05       Impact factor: 2.672

2.  The elevated preoperative neutrophil-to-lymphocyte ratio predicts poor prognosis in intrahepatic cholangiocarcinoma patients undergoing hepatectomy.

Authors:  Qing Chen; Liu-Xiao Yang; Xue-Dong Li; Dan Yin; Shi-Ming Shi; Er-Bao Chen; Lei Yu; Zheng-Jun Zhou; Shao-Lai Zhou; Ying-Hong Shi; Jia Fan; Jian Zhou; Zhi Dai
Journal:  Tumour Biol       Date:  2015-02-12

Review 3.  Prognostic role of neutrophils to lymphocytes ratio in patients with acute pulmonary embolism: a systematic review and meta-analysis of the literature.

Authors:  Silvia Galliazzo; Olga Nigro; Lorenza Bertù; Luigina Guasti; Anna Maria Grandi; Walter Ageno; Francesco Dentali
Journal:  Intern Emerg Med       Date:  2018-03-05       Impact factor: 3.397

4.  Evaluation of Prognosis and Risk of Death by Neutrophil/Lymphocyte Ratio, C-Reactive Protein/Albumin Ratio and Plasma D-Dimer in Patients with Pulmonary Thromboembolism.

Authors:  Tiantian Shan; Xinran Li; Min Yan; Xiangtao Pan
Journal:  Int J Gen Med       Date:  2021-12-01

5.  The Association of Neutrophil-Lymphocyte Ratio with Venous Thromboembolism: A Systematic Review and Meta-Analysis.

Authors:  Jingjing Hu; Zhaobin Cai; Yidan Zhou
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 3.512

6.  The values of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in predicting 30 day mortality in patients with acute pulmonary embolism.

Authors:  Yaqing Ma; Yimin Mao; Xuegai He; Yuxia Sun; Shenshen Huang; Jiayong Qiu
Journal:  BMC Cardiovasc Disord       Date:  2016-06-04       Impact factor: 2.298

7.  Diagnostic Value of Neutrophil Lymphocyte Ratio and D-Dimer as Biological Markers of Deep Vein Thrombosis in Patients Presenting with Unilateral Limb Edema.

Authors:  Ikhwan Rinaldi; Rachmat Hamonangan; Mohamad Syahrir Azizi; Rahmat Cahyanur; Fadila Wirawan; Atikah Isna Fatya; Ageng Budiananti; Kevin Winston
Journal:  J Blood Med       Date:  2021-05-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.